Fulcrum Therapeutics, Inc. (FULC)
3.86
+0.02
(+0.52%)
USD |
NASDAQ |
Aug 25, 16:00
3.83
-0.03
(-0.78%)
After-Hours: 19:59
Fulcrum Therapeutics Shareholders Equity (Quarterly) : 310.70M for June 30, 2026
Shareholders Equity (Quarterly) Chart
Sep '18
Jan '19
May '19
285.00
270.00
255.00
240.00
Historical Shareholders Equity (Quarterly) Data
| Date | Value |
|---|---|
| June 30, 2026 | 310.70M |
| March 31, 2026 | 333.30M |
| December 31, 2025 | 349.00M |
| September 30, 2025 | 198.37M |
| June 30, 2025 | 214.38M |
| March 31, 2025 | 228.49M |
| December 31, 2024 | 243.03M |
| September 30, 2024 | 257.29M |
| June 30, 2024 | 273.79M |
| March 31, 2024 | 213.59M |
| December 31, 2023 | 235.19M |
| September 30, 2023 | 255.46M |
| June 30, 2023 | 275.43M |
| March 31, 2023 | 296.26M |
| December 31, 2022 | 198.94M |
| September 30, 2022 | 221.41M |
| Date | Value |
|---|---|
| June 30, 2022 | 160.76M |
| March 31, 2022 | 189.16M |
| December 31, 2021 | 211.54M |
| September 30, 2021 | 230.61M |
| June 30, 2021 | 110.89M |
| March 31, 2021 | 127.75M |
| December 31, 2020 | 95.18M |
| September 30, 2020 | 104.98M |
| June 30, 2020 | 122.13M |
| March 31, 2020 | 70.63M |
| December 31, 2019 | 87.15M |
| September 30, 2019 | 102.13M |
| June 30, 2019 | -111.68M |
| March 31, 2019 | -99.69M |
| December 31, 2018 | -63.67M |
Shareholders' Equity Definition
Represents the value of Shareholders' Equity as of the close of the report date, belonging to both Preferred and Common Equity Shareholders.
Shareholders Equity (Quarterly) Range, Past 5 Years
--
Minimum
--
Maximum
--
Average
--
Median
Shareholders Equity (Quarterly) Benchmarks
| Cocrystal Pharma, Inc. | 1.044M |
| CNBX Pharmaceuticals, Inc. | -2.660M |
| GB Sciences, Inc. | -- |
| Arvinas, Inc. | 562.20M |
| Definium Therapeutics, Inc. | 918.68M |
Shareholders Equity (Quarterly) Related Metrics
| Total Assets (Quarterly) | 323.95M |
| Total Liabilities (Quarterly) | 13.26M |
| Debt to Equity Ratio | 0.017 |
| Current Ratio | 31.35 |
| Net Debt Paydown Yield | 0.20% |